File:Ampligen-response-2016.jpg

Title: (or description)
Ampligen (Rintatinamol) trial results summary. Figure 5. AMP-516 plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Plot of ET difference from baseline in seconds at 40 weeks treatment (ordinate) per each patient (abscissa). Reproduced from Strayer et al. Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME): Characteristics of responders to Rintatolimod. J Drug Res Dev 2015;1: doi http://dx.doiorg/10.16966/jdrd.103. Key: ET - Exercise Tolerance test

Author: (or citation)
Disclosure: Author William Mitchell is Chairman of the board of AIM ImmunoTech, who have developed Ampligen.

Source: (e.g. internet address)
Figure 5.